Contemporary indications for and outcomes of hepatic resection for neuroendocrine liver metastases

Table 3 Significant predictors of 30-d overall morbidity among patients undergoing hepatectomy for neuroendocrine liver metastases based on univariate logistic regression analysis

	OR	95%CI	P value
Age > 60	0.931	0.658-1.316	0.6835
Male gender	1.232	0.890-1.707	0.2092
ASA class ≥ 3	2.418	1.422-4.113	0.0011
BMI > 27	1.030	0.743-1.428	0.8596
Preop biliary stent	2.562	0.850-7.719	0.0946
Viral hepatitis	2.538	0.841-7.660	0.0983
Concomitant bowel resection	1.278	0.885-1.844	0.1906
Concomitant cholecystectomy	1.094	0.749-1.598	0.6431
Concomitant pancreatectomy	1.579	0.626-3.984	0.3335
Open approach	1.943	1.218-3.102	0.0053
Size < 2 cm (ref)
Size 2-5 cm	0.989	0.645-1.516	0.9591
Size > 5 cm	1.397	0.882-2.215	0.1546
Number of tumors > 1	0.984	0.681-1.422	0.9317
Right/left/triseg hepatectomy	1.660	1.169-2.355	0.0046
Abnormal liver texture	1.340	0.818-2.193	0.2447
Intraoperative ablation	0.686	0.476-0.988	0.0431
Biliary reconstruction	3.979	1.317-12.023	0.0144
Operative time > 230 min	2.043	1.407-2.968	0.0002
Pringle	1.429	0.986-2.070	0.0593

OR: Odds ratio; CI: Confidence intervals; ASA: American Society of Anesthesiologists; BMI: Body mass index.